 |
PDBsum entry 2bnh
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
264:1028-1043
(1996)
|
|
PubMed id:
|
|
|
|
|
| |
|
Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A.
|
|
B.Kobe,
J.Deisenhofer.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
We describe the mechanism of ribonuclease inhibition by ribonuclease inhibitor,
a protein built of leucine-rich repeats, based on the crystal structure of the
complex between the inhibitor and ribonuclease A. The structure was determined
by molecular replacement and refined to an Rcryst of 19.4% at 2.5 A resolution.
Ribonuclease A binds to the concave region of the inhibitor protein comprising
its parallel beta-sheet and loops. The inhibitor covers the ribonuclease active
site and directly contacts several active-site residues. The inhibitor only
partially mimics the RNase-nucleotide interaction and does not utilize the p1
phosphate-binding pocket of ribonuclease A, where a sulfate ion remains bound.
The 2550 A2 of accessible surface area buried upon complex formation may be one
of the major contributors to the extremely tight association (Ki = 5.9 x 10(-14)
M). The interaction is predominantly electrostatic; there is a high chemical
complementarity with 18 putative hydrogen bonds and salt links, but the shape
complementarity is lower than in most other protein-protein complexes.
Ribonuclease inhibitor changes its conformation upon complex formation; the
conformational change is unusual in that it is a plastic reorganization of the
entire structure without any obvious hinge and reflects the conformational
flexibility of the structure of the inhibitor. There is a good agreement between
the crystal structure and other biochemical studies of the interaction. The
structure suggests that the conformational flexibility of RI and an unusually
large contact area that compensates for a lower degree of complementarity may be
the principal reasons for the ability of RI to potently inhibit diverse
ribonucleases. However, the inhibition is lost with amphibian ribonucleases that
have substituted most residues corresponding to inhibitor-binding residues in
RNase A, and with bovine seminal ribonuclease that prevents inhibitor binding by
forming a dimer.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Figure 3. Conformational changes
in RI. The models of RI from the
RNase A-RI complex (continuous
lines) and RI from the lithium
sulfate crystals (broken lines) were
superimposed on the high-resol-
ution model of free RI with the
program INSIGHT (using only the
C
a
atoms). The r.m.s. deviations of
the C
a
atoms are shown as thin
lines, and the fourth-order poly-
nomial curves fitted to the r.m.s.
deviations curves are shown as
thick lines.
|
 |
Figure 4.
Figure 4. An annealed omit electron density in the active site of RNase A. An 8 Å sphere around the sulfate ion
in the RNase active site was omitted and the immediate surrounding atoms consisting of a 3 Å shell were restrained
to avoid artificial movement into the omitted region. Simulated annealing was run with a starting temperature of
1000 Å . The stereo view of the electron density calculated with the phases derived from the omitted model and
coefficients =Fobs= - =Fcalc= for data between 40 and 2.5 Å , was contoured at 3s and plotted with a program written by
D. Xia. Superimposed is the model of the RNase A-RI complex. RNase A residues are indicated with E, and RI residues
are indicated with I.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(1996,
264,
1028-1043)
copyright 1996.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
W.Wriggers
(2012).
Conventions and workflows for using Situs.
|
| |
Acta Crystallogr D Biol Crystallogr,
68,
344-351.
|
 |
|
|
|
|
 |
C.Giancola,
C.Ercole,
I.Fotticchia,
R.Spadaccini,
E.Pizzo,
G.D'Alessio,
and
D.Picone
(2011).
Structure-cytotoxicity relationships in bovine seminal ribonuclease: new insights from heat and chemical denaturation studies on variants.
|
| |
FEBS J,
278,
111-122.
|
 |
|
|
|
|
 |
E.Karaca,
and
A.M.Bonvin
(2011).
A multidomain flexible docking approach to deal with large conformational changes in the modeling of biomolecular complexes.
|
| |
Structure,
19,
555-565.
|
 |
|
|
|
|
 |
U.Arnold,
F.Leich,
P.Neumann,
H.Lilie,
and
R.Ulbrich-Hofmann
(2011).
Crystal structure of RNase A tandem enzymes and their interaction with the cytosolic ribonuclease inhibitor.
|
| |
FEBS J,
278,
331-340.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
W.Yang
(2011).
Nucleases: diversity of structure, function and mechanism.
|
| |
Q Rev Biophys,
44,
1.
|
 |
|
|
|
|
 |
J.R.Weber
(2009).
ProteinShader: illustrative rendering of macromolecules.
|
| |
BMC Struct Biol,
9,
19.
|
 |
|
|
|
|
 |
K.L.Hindle,
J.Bella,
and
S.C.Lovell
(2009).
Quantitative analysis and prediction of curvature in leucine-rich repeat proteins.
|
| |
Proteins,
77,
342-358.
|
 |
|
|
|
|
 |
A.K.Beck,
H.I.Pass,
M.Carbone,
and
H.Yang
(2008).
Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies.
|
| |
Future Oncol,
4,
341-349.
|
 |
|
|
|
|
 |
A.May,
and
M.Zacharias
(2008).
Energy minimization in low-frequency normal modes to efficiently allow for global flexibility during systematic protein-protein docking.
|
| |
Proteins,
70,
794-809.
|
 |
|
|
|
|
 |
D.Marks,
and
A.Segal
(2008).
Innate immunity in inflammatory bowel disease: a disease hypothesis.
|
| |
J Pathol,
214,
260-266.
|
 |
|
|
|
|
 |
G.R.Marshall,
J.A.Feng,
and
D.J.Kuster
(2008).
Back to the future: ribonuclease A.
|
| |
Biopolymers,
90,
259-277.
|
 |
|
|
|
|
 |
G.Torrent,
A.Benito,
J.Castro,
M.Ribó,
and
M.Vilanova
(2008).
Contribution of the C30/C75 disulfide bond to the biological properties of onconase.
|
| |
Biol Chem,
389,
1127-1136.
|
 |
|
|
|
|
 |
R.F.Turcotte,
and
R.T.Raines
(2008).
Interaction of onconase with the human ribonuclease inhibitor protein.
|
| |
Biochem Biophys Res Commun,
377,
512-514.
|
 |
|
|
|
|
 |
R.F.Turcotte,
and
R.T.Raines
(2008).
Design and characterization of an HIV-specific ribonuclease zymogen.
|
| |
AIDS Res Hum Retroviruses,
24,
1357-1363.
|
 |
|
|
|
|
 |
T.J.Rutkoski,
and
R.T.Raines
(2008).
Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.
|
| |
Curr Pharm Biotechnol,
9,
185-189.
|
 |
|
|
|
|
 |
E.Andersen-Nissen,
K.D.Smith,
R.Bonneau,
R.K.Strong,
and
A.Aderem
(2007).
A conserved surface on Toll-like receptor 5 recognizes bacterial flagellin.
|
| |
J Exp Med,
204,
393-403.
|
 |
|
|
|
|
 |
G.N.Phillips,
B.G.Fox,
J.L.Markley,
B.F.Volkman,
E.Bae,
E.Bitto,
C.A.Bingman,
R.O.Frederick,
J.G.McCoy,
B.L.Lytle,
B.S.Pierce,
J.Song,
and
S.N.Twigger
(2007).
Structures of proteins of biomedical interest from the Center for Eukaryotic Structural Genomics.
|
| |
J Struct Funct Genomics,
8,
73-84.
|
 |
|
|
|
|
 |
L.D.Lavis,
T.J.Rutkoski,
and
R.T.Raines
(2007).
Tuning the pK(a) of fluorescein to optimize binding assays.
|
| |
Anal Chem,
79,
6775-6782.
|
 |
|
|
|
|
 |
M.Ghosh,
G.Meiss,
A.M.Pingoud,
R.E.London,
and
L.C.Pedersen
(2007).
The nuclease a-inhibitor complex is characterized by a novel metal ion bridge.
|
| |
J Biol Chem,
282,
5682-5690.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
N.Matsushima,
T.Tanaka,
P.Enkhbayar,
T.Mikami,
M.Taga,
K.Yamada,
and
Y.Kuroki
(2007).
Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors.
|
| |
BMC Genomics,
8,
124.
|
 |
|
|
|
|
 |
R.J.Johnson,
J.G.McCoy,
C.A.Bingman,
G.N.Phillips,
and
R.T.Raines
(2007).
Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein.
|
| |
J Mol Biol,
368,
434-449.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.J.Johnson,
L.D.Lavis,
and
R.T.Raines
(2007).
Intraspecies regulation of ribonucleolytic activity.
|
| |
Biochemistry,
46,
13131-13140.
|
 |
|
|
|
|
 |
B.Zhou,
S.Qu,
G.Liu,
M.Dolan,
H.Sakai,
G.Lu,
M.Bellizzi,
and
G.L.Wang
(2006).
The eight amino-acid differences within three leucine-rich repeats between Pi2 and Piz-t resistance proteins determine the resistance specificity to Magnaporthe grisea.
|
| |
Mol Plant Microbe Interact,
19,
1216-1228.
|
 |
|
|
|
|
 |
H.Yagi,
M.Ueda,
H.Jinno,
K.Aiura,
S.Mikami,
H.Tada,
M.Seno,
H.Yamada,
and
M.Kitajima
(2006).
Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties.
|
| |
Cancer Sci,
97,
1315-1320.
|
 |
|
|
|
|
 |
L.M.Kallay,
A.McNickle,
P.J.Brennwald,
A.L.Hubbard,
and
L.T.Braiterman
(2006).
Scribble associates with two polarity proteins, Lgl2 and Vangl2, via distinct molecular domains.
|
| |
J Cell Biochem,
99,
647-664.
|
 |
|
|
|
|
 |
S.Schornack,
A.Meyer,
P.Römer,
T.Jordan,
and
T.Lahaye
(2006).
Gene-for-gene-mediated recognition of nuclear-targeted AvrBs3-like bacterial effector proteins.
|
| |
J Plant Physiol,
163,
256-272.
|
 |
|
|
|
|
 |
Z.Pancer,
and
M.D.Cooper
(2006).
The evolution of adaptive immunity.
|
| |
Annu Rev Immunol,
24,
497-518.
|
 |
|
|
|
|
 |
A.Benito,
M.Ribó,
and
M.Vilanova
(2005).
On the track of antitumour ribonucleases.
|
| |
Mol Biosyst,
1,
294-302.
|
 |
|
|
|
|
 |
C.Korn,
S.R.Scholz,
O.Gimadutdinow,
R.Lurz,
A.Pingoud,
and
G.Meiss
(2005).
Interaction of DNA fragmentation factor (DFF) with DNA reveals an unprecedented mechanism for nuclease inhibition and suggests that DFF can be activated in a DNA-bound state.
|
| |
J Biol Chem,
280,
6005-6015.
|
 |
|
|
|
|
 |
E.E.Büllesbach,
and
C.Schwabe
(2005).
The trap-like relaxin-binding site of the leucine-rich G-protein-coupled receptor 7.
|
| |
J Biol Chem,
280,
14051-14056.
|
 |
|
|
|
|
 |
J.Choe,
M.S.Kelker,
and
I.A.Wilson
(2005).
Crystal structure of human toll-like receptor 3 (TLR3) ectodomain.
|
| |
Science,
309,
581-585.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.A.Dickson,
M.C.Haigis,
and
R.T.Raines
(2005).
Ribonuclease inhibitor: structure and function.
|
| |
Prog Nucleic Acid Res Mol Biol,
80,
349-374.
|
 |
|
|
|
|
 |
M.N.Alder,
I.B.Rogozin,
L.M.Iyer,
G.V.Glazko,
M.D.Cooper,
and
Z.Pancer
(2005).
Diversity and function of adaptive immune receptors in a jawless vertebrate.
|
| |
Science,
310,
1970-1973.
|
 |
|
|
|
|
 |
Z.Wang,
L.Zhang,
J.Lu,
and
L.Zhang
(2005).
Analysis of the interactions of ribonuclease inhibitor with kanamycin.
|
| |
J Mol Model,
11,
80-86.
|
 |
|
|
|
|
 |
K.Kumar,
M.Brady,
and
R.Shapiro
(2004).
Selective abolition of pancreatic RNase binding to its inhibitor protein.
|
| |
Proc Natl Acad Sci U S A,
101,
53-58.
|
 |
|
|
|
|
 |
M.G.Martínez Zamora,
A.P.Castagnaro,
and
J.C.Díaz Ricci
(2004).
Isolation and diversity analysis of resistance gene analogues (RGAs) from cultivated and wild strawberries.
|
| |
Mol Genet Genomics,
272,
480-487.
|
 |
|
|
|
|
 |
P.Forrer,
H.K.Binz,
M.T.Stumpp,
and
A.Plückthun
(2004).
Consensus design of repeat proteins.
|
| |
Chembiochem,
5,
183-189.
|
 |
|
|
|
|
 |
A.Bracale,
F.Castaldi,
L.Nitsch,
and
G.D'Alessio
(2003).
A role for the intersubunit disulfides of seminal RNase in the mechanism of its antitumor action.
|
| |
Eur J Biochem,
270,
1980-1987.
|
 |
|
|
|
|
 |
A.Di Matteo,
L.Federici,
B.Mattei,
G.Salvi,
K.A.Johnson,
C.Savino,
G.De Lorenzo,
D.Tsernoglou,
and
F.Cervone
(2003).
The crystal structure of polygalacturonase-inhibiting protein (PGIP), a leucine-rich repeat protein involved in plant defense.
|
| |
Proc Natl Acad Sci U S A,
100,
10124-10128.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
B.D.Smith,
M.B.Soellner,
and
R.T.Raines
(2003).
Potent inhibition of ribonuclease A by oligo(vinylsulfonic acid).
|
| |
J Biol Chem,
278,
20934-20938.
|
 |
|
|
|
|
 |
B.F.Holt,
D.A.Hubert,
and
J.L.Dangl
(2003).
Resistance gene signaling in plants--complex similarities to animal innate immunity.
|
| |
Curr Opin Immunol,
15,
20-25.
|
 |
|
|
|
|
 |
D.B.Gordon,
G.K.Hom,
S.L.Mayo,
and
N.A.Pierce
(2003).
Exact rotamer optimization for protein design.
|
| |
J Comput Chem,
24,
232-243.
|
 |
|
|
|
|
 |
H.Wu,
and
S.M.King
(2003).
Backbone dynamics of dynein light chains.
|
| |
Cell Motil Cytoskeleton,
54,
267-273.
|
 |
|
|
|
|
 |
J.K.Bell,
G.E.Mullen,
C.A.Leifer,
A.Mazzoni,
D.R.Davies,
and
D.M.Segal
(2003).
Leucine-rich repeats and pathogen recognition in Toll-like receptors.
|
| |
Trends Immunol,
24,
528-533.
|
 |
|
|
|
|
 |
J.Matousek,
G.Gotte,
P.Pouckova,
J.Soucek,
T.Slavik,
F.Vottariello,
and
M.Libonati
(2003).
Antitumor activity and other biological actions of oligomers of ribonuclease A.
|
| |
J Biol Chem,
278,
23817-23822.
|
 |
|
|
|
|
 |
M.C.Haigis,
E.L.Kurten,
and
R.T.Raines
(2003).
Ribonuclease inhibitor as an intracellular sentry.
|
| |
Nucleic Acids Res,
31,
1024-1032.
|
 |
|
|
|
|
 |
A.Russo,
A.Antignani,
C.Giancola,
and
G.D'Alessio
(2002).
Engineering the refolding pathway and the quaternary structure of seminal ribonuclease by newly introduced disulfide bridges.
|
| |
J Biol Chem,
277,
48643-48649.
|
 |
|
|
|
|
 |
J.Matousek,
P.Poucková,
J.Soucek,
and
J.Skvor
(2002).
PEG chains increase aspermatogenic and antitumor activity of RNase A and BS-RNase enzymes.
|
| |
J Control Release,
82,
29-37.
|
 |
|
|
|
|
 |
M.Santra,
C.C.Reed,
and
R.V.Iozzo
(2002).
Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope.
|
| |
J Biol Chem,
277,
35671-35681.
|
 |
|
|
|
|
 |
B.Mattei,
F.Cervone,
and
P.Roepstorff
(2001).
The Interaction Between Endopolygalacturonase From Fusarium Moniliforme and PGIP from Phaseolus Vulgaris Studied by Surface Plasmon Resonance and Mass Spectrometry.
|
| |
Comp Funct Genomics,
2,
359-364.
|
 |
|
|
|
|
 |
P.A.Leland,
K.E.Staniszewski,
B.M.Kim,
and
R.T.Raines
(2001).
Endowing human pancreatic ribonuclease with toxicity for cancer cells.
|
| |
J Biol Chem,
276,
43095-43102.
|
 |
|
|
|
|
 |
P.A.Leland,
and
R.T.Raines
(2001).
Cancer chemotherapy--ribonucleases to the rescue.
|
| |
Chem Biol,
8,
405-413.
|
 |
|
|
|
|
 |
Y.G.Hsiung,
H.C.Chang,
J.L.Pellequer,
R.La Valle,
S.Lanker,
and
C.Wittenberg
(2001).
F-box protein Grr1 interacts with phosphorylated targets via the cationic surface of its leucine-rich repeat.
|
| |
Mol Cell Biol,
21,
2506-2520.
|
 |
|
|
|
|
 |
L.E.Bretscher,
R.L.Abel,
and
R.T.Raines
(2000).
A ribonuclease A variant with low catalytic activity but high cytotoxicity.
|
| |
J Biol Chem,
275,
9893-9896.
|
 |
|
|
|
|
 |
N.Matsushima,
T.Ohyanagi,
T.Tanaka,
and
R.H.Kretsinger
(2000).
Super-motifs and evolution of tandem leucine-rich repeats within the small proteoglycans--biglycan, decorin, lumican, fibromodulin, PRELP, keratocan, osteoadherin, epiphycan, and osteoglycin.
|
| |
Proteins,
38,
210-225.
|
 |
|
|
|
|
 |
C.Z.Chen,
and
R.Shapiro
(1999).
Superadditive and subadditive effects of "hot spot" mutations within the interfaces of placental ribonuclease inhibitor with angiogenin and ribonuclease A.
|
| |
Biochemistry,
38,
9273-9285.
|
 |
|
|
|
|
 |
F.Leckie,
B.Mattei,
C.Capodicasa,
A.Hemmings,
L.Nuss,
B.Aracri,
G.De Lorenzo,
and
F.Cervone
(1999).
The specificity of polygalacturonase-inhibiting protein (PGIP): a single amino acid substitution in the solvent-exposed beta-strand/beta-turn region of the leucine-rich repeats (LRRs) confers a new recognition capability.
|
| |
EMBO J,
18,
2352-2363.
|
 |
|
|
|
|
 |
P.A.Leland,
L.W.Schultz,
B.M.Kim,
and
R.T.Raines
(1998).
Ribonuclease A variants with potent cytotoxic activity.
|
| |
Proc Natl Acad Sci U S A,
95,
10407-10412.
|
 |
|
|
|
|
 |
A.C.Papageorgiou,
R.Shapiro,
and
K.R.Acharya
(1997).
Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution.
|
| |
EMBO J,
16,
5162-5177.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |